Navigation Links
InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
Date:9/13/2010

InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which InterMune has completed the Phase 3 CAPACITY program in patients with IPF. A Marketing Authorization Application (MAA) for pirfenidone is under review by the European Medicines Agency (EMA). The hepatology portfolio includes the HCV protease inhibitor compound danoprevir (also known as RG7227 and ITMN-191) that entered Phase 2b in August 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, which reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated regulatory timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon these data, in combination with the other efficacy and safety results the company has submitted in support of its New Drug Application (NDA) and MAA filings. Furthermore, while the Pulmonary-Allergy Drugs Advisory Commi
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune to Release Second Quarter Financial Results on July 27
2. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
3. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
4. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
5. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
6. InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
7. InterMune to Present at Deutsche Bank Biotech Confab
8. InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
9. InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
10. InterMune to Present at JMP Securities Conference
11. InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... IRVINE, Calif. , Aug. 31, 2015 /PRNewswire/ ... business and government, where regulations are often strict ... environment is driving a demand for professionals who ... interpret these regulations across a product lifecycle and ... organization. The University of California, Irvine Extension ...
(Date:8/31/2015)... FLINT, Mich. , Aug. 31, 2015  Diplomat Pharmacy, ... pharmacy, has announced that Phil Hagerman , Chairman & ... four upcoming investor conferences. Mr. Hagerman and ... 2015 Healthcare Conference in Boston on ... Mr. Hagerman and Mr. Whelan are also scheduled to participate ...
(Date:8/31/2015)... , Aug. 31, 2015  Qualcomm Incorporated ... subsidiary, Qualcomm Life, Inc., is collaborating ... chronic care management solutions powered by Qualcomm Life,s ... Platform to enable continuous care, informed interventions and ... announced at Qualcomm Life,s annual Connect 2015 ...
Breaking Medicine Technology:UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Diplomat to Participate in Upcoming Investor Conferences 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
(Date:9/1/2015)... ... ... September is Baby Safety Month, and Lightning Labels wants to ... ones' safety top of mind at all times. , Sponsored by the Juvenile Products ... JPMA's Baby Safety Zone website, this year's theme is A Room with A Safe ...
(Date:9/1/2015)... ... September 01, 2015 , ... The ... Systems, has become a leader in podiatric, surgical and wound care ... Superwounds Conferences place top national speakers at the podium and across the table ...
(Date:8/31/2015)... ... September 01, 2015 , ... ... the release of ten hours of new premium on-demand video Evidence Based ... , Athletic Trainers certified before 2014 must complete 50 CEUs before December 31, ...
(Date:8/31/2015)... (PRWEB) , ... September 01, 2015 , ... ... to eliminate chronic back pain – once required a long, arduous recovery. However, ... hospital stay, less pain, less blood loss and minimal muscle damage. These advantages ...
(Date:8/31/2015)... ... 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics proudly announces that Kathy ... by Modern Luxury’s The Atlantan Magazine. , This award for the Sculpted ... Her idea and vision to bring to Atlanta a true luxury experience in ...
Breaking Medicine News(10 mins):Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:PRESENT e-Learning Systems Announces their 2016 Podiatry and Wound Care Medical Education Conference Schedule 2Health News:Evidence Based Practice Courses: CEUs For Athletic Trainers Just Released 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 3
... may have a way to make the powerful cancer drug ... some cancers. The chemotherapeutic agent used in combination with other ... or failure in about 30 percent of users, although the ... to protect the kidneys is advise patients to drink more ...
... News) -- A man,s heart disease risk after the age of ... body size and placenta size when he was born, a new ... lifetime nutrition and the early growth of her child," study lead ... University of Southampton in the United Kingdom, said in a news ...
... study published in the journal Clinical Cardiology ... resynchronization therapy (CRT) improves patients, libido, erectile dysfunction, and ... complex clinical syndrome characterized by fatigue and exercise intolerance. ... CRT, which is a type of pacemaker that paces ...
... Physicians can help their patients follow prescribed ... chronic disease management by using a three-pronged ... the University of California, Riverside, Texas State University-San ... The Information-Motivation-Strategy (IMS) Model developed after ...
... at the University of Southern California have pinned down ... survival trait: our ability to comprehend a sceneeven one ... The key is to process the interacting objects ... according to corresponding author Irving Biederman, professor of psychology ...
... hurdles in obtaining an appointment for care with an ... of Medicine at the University of Pennnsylvania that will ... meeting of American Society of Clinical Oncology (Abstract #6128). ... an appointment, with just 22 percent of them obtaining ...
Cached Medicine News:Health News:Cause and potential treatment found for cancer drug's kidney toxicity 2Health News:Male Heart Disease May Be Linked to Mom's Lifetime Nutrition 2Health News:Researchers develop strategy to improve patient adherence 2Health News:Researchers develop strategy to improve patient adherence 3Health News:USC study locates the source of key brain function 2Health News:Two-thirds of newly diagnosed cancer patients unable to obtain oncology appointments 2
... KeraCel Ophthalmic Products are ... formulation of lint-free MEROCEL polyvinyl ... configured to be beneficial to ... being absorbent, and yet firm ...
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: